EGFR and non-small cell lung carcinoma: Furthermore, increased ILT4 and PD-L1 co-expression in human NSCLC tissues with wild-type EGFR suggested that the combination blockade of ILT4 and PD-L1 is clinically feasible for a broad spectrum of NSCLC patients.